DK4181920T3 - Kat6-inhibitor og kombinationer til behandling af brystkræft - Google Patents

Kat6-inhibitor og kombinationer til behandling af brystkræft

Info

Publication number
DK4181920T3
DK4181920T3 DK21749550.6T DK21749550T DK4181920T3 DK 4181920 T3 DK4181920 T3 DK 4181920T3 DK 21749550 T DK21749550 T DK 21749550T DK 4181920 T3 DK4181920 T3 DK 4181920T3
Authority
DK
Denmark
Prior art keywords
cat6
inhibitor
combinations
treatment
breast cancer
Prior art date
Application number
DK21749550.6T
Other languages
English (en)
Inventor
Paul Anthony Stupple
Anthony Mazurek
Kim Timothy Arndt
Lei Chen
Maximillian Todd Follettie
David Scott Fruhling
Pei-Pei Kung
Wenyan Zhong
Philip Michael Tedeschi
Original Assignee
Pfizer
Ctxt Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Ctxt Pty Ltd filed Critical Pfizer
Application granted granted Critical
Publication of DK4181920T3 publication Critical patent/DK4181920T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK21749550.6T 2020-07-15 2021-07-15 Kat6-inhibitor og kombinationer til behandling af brystkræft DK4181920T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063052215P 2020-07-15 2020-07-15
US202163211044P 2021-06-16 2021-06-16
PCT/EP2021/069787 WO2022013369A1 (en) 2020-07-15 2021-07-15 Kat6 inhibitor methods and combinations for cancer treatment

Publications (1)

Publication Number Publication Date
DK4181920T3 true DK4181920T3 (da) 2025-09-29

Family

ID=77179980

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21749550.6T DK4181920T3 (da) 2020-07-15 2021-07-15 Kat6-inhibitor og kombinationer til behandling af brystkræft

Country Status (17)

Country Link
EP (2) EP4181920B1 (da)
JP (1) JP2022019654A (da)
KR (1) KR102976842B1 (da)
AU (2) AU2021308406A1 (da)
BR (1) BR112023000687A2 (da)
CA (1) CA3189410A1 (da)
DK (1) DK4181920T3 (da)
ES (1) ES3050760T3 (da)
FI (1) FI4181920T3 (da)
HU (1) HUE073220T2 (da)
IL (1) IL299871A (da)
MX (1) MX2023000735A (da)
PT (1) PT4181920T (da)
SI (1) SI4181920T1 (da)
TW (1) TW202216131A (da)
WO (1) WO2022013369A1 (da)
ZA (1) ZA202300875B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114072394A (zh) 2019-04-25 2022-02-18 拜耳股份公司 用于治疗癌症的酰基磺酰胺
US20240400545A1 (en) * 2021-07-05 2024-12-05 Hangzhou Innogate Pharma Co., Ltd. Compound serving as kat6 inhibitor
MX2024005839A (es) 2021-11-16 2024-06-26 Insilico Medicine Ip Ltd Inhibidores de lisina acetiltransferasa 6a (kat6a) y usos de los mismos.
AU2022400308B2 (en) * 2021-12-02 2026-02-12 Pfizer Inc. Cdk4 inhibitor for the treatment of cancer
CN116621859B (zh) * 2022-02-18 2026-06-12 山东轩竹医药科技有限公司 三并环类kat6抑制剂
US12187732B2 (en) 2022-03-28 2025-01-07 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
AU2023295547A1 (en) * 2022-06-16 2025-01-09 Prelude Therapeutics Incorporated Kat6 targeting compounds with ubiquitin ligase binding moiety
JP2025533719A (ja) 2022-07-29 2025-10-09 ファイザー・インク がんの治療のためのkat6阻害剤を含む投与レジメン
EP4604961A1 (en) * 2022-10-18 2025-08-27 Pfizer Inc. Compounds for the treatment of cancer
EP4692094A1 (en) * 2023-03-27 2026-02-11 Beijing Konruns Pharmaceutical Co., Ltd. Sulfonamide compound, pharmaceutical composition thereof and use thereof
KR20250164842A (ko) 2023-03-30 2025-11-25 화이자 인코포레이티드 Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법
AR132470A1 (es) * 2023-04-19 2025-07-02 Insilico Medicine Ip Ltd Inhibidor de lisina-acetiltransferasa 6a (kat6a), combinaciones y usos del mismo
AU2024325442A1 (en) 2023-08-14 2026-03-26 Shanghai Henlius Biologics Co., Ltd. Sulfonamide compound, and preparation method therefor and use thereof
CN117448454B (zh) * 2023-10-30 2025-09-30 赣南医科大学 Kat6a在制备结直肠癌肝转移诊断试剂盒中的应用
WO2025141469A1 (en) 2023-12-26 2025-07-03 Pfizer Inc. Crystalline form of 2-methoxy-n-{4-methoxy-6-[(1h-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide
WO2026060321A1 (en) * 2024-09-13 2026-03-19 Olema Pharmaceuticals, Inc. Kat6 degrader compounds and method thereof
WO2026133163A1 (en) 2024-12-19 2026-06-25 Pfizer Inc. Film coated solid dosage forms for management of dysgeusia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
DE602004017474D1 (de) 2003-07-11 2008-12-11 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
KR20090052385A (ko) 2006-09-08 2009-05-25 화이자 프로덕츠 인크. 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온의합성
DK3431475T3 (da) 2013-02-21 2021-05-25 Pfizer Faste former af en selektiv CDK4/6-hæmmer
GB201510019D0 (en) * 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
GB201713962D0 (en) 2017-08-31 2017-10-18 Ctxt Pty Ltd Compounds
CN118286225A (zh) 2018-04-26 2024-07-05 辉瑞公司 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
EP3850381A2 (en) 2018-09-10 2021-07-21 3M Innovative Properties Company Electrical power cable monitoring device including partial discharge sensor
CN114072394A (zh) * 2019-04-25 2022-02-18 拜耳股份公司 用于治疗癌症的酰基磺酰胺
SI4299135T1 (sl) * 2019-06-18 2025-12-31 Pfizer Inc. Benzizoksazolni sulfonamidni derivati

Also Published As

Publication number Publication date
KR102976842B1 (ko) 2026-06-15
CN116113407A (zh) 2023-05-12
JP2022019654A (ja) 2022-01-27
IL299871A (en) 2023-03-01
TW202216131A (zh) 2022-05-01
HUE073220T2 (hu) 2026-01-28
WO2022013369A1 (en) 2022-01-20
BR112023000687A2 (pt) 2023-02-07
EP4667055A3 (en) 2026-02-25
KR20230058614A (ko) 2023-05-03
ZA202300875B (en) 2023-09-27
SI4181920T1 (sl) 2026-01-30
EP4181920A1 (en) 2023-05-24
EP4181920B1 (en) 2025-09-10
MX2023000735A (es) 2023-02-13
AU2025200238A1 (en) 2025-01-30
ES3050760T3 (en) 2025-12-22
EP4667055A2 (en) 2025-12-24
AU2021308406A1 (en) 2023-02-23
PT4181920T (pt) 2025-11-04
CA3189410A1 (en) 2022-01-20
FI4181920T3 (fi) 2025-11-20

Similar Documents

Publication Publication Date Title
DK4161935T3 (da) Brm-målrettende forbindelser og tilhørende anvendelsesmetoder
DK3902803T3 (da) Aza-heterobicykliske inhibitorer af mat2a og anvendelsesfremgangsmåder til behandling af kræft
DK4096717T3 (da) Behandling af cancer
DK3986897T3 (da) EGFR-hæmmer til cancerbehandling
DK3860990T3 (da) Inhibitorer for YAP/TAZ-TEAD interaktion og disses anvendelse ved behandlingen af cancer
DK3678668T3 (da) ENPP1-inhibitorer og deres anvendelse til behandling af kræft
DK3774789T3 (da) BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse
IL269150A (en) Compositions and methods for treating cancer
IL268814A (en) Compositions and methods for treatment of cancer
DK3826667T3 (da) Claudin6-antistoffer og fremgangsmåder til behandling af kræft
IL268676A (en) Inhibition of smarca2 for treatment of cancer
IL270511A (en) Combination therapies using niraparib and pembrolizumab for treating cancer
IL282776A (en) Plasmid constructs for treating cancer and methods of use
DK3807316T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer
DK3755816T3 (da) Fremgangsmåder til påvisning og behandling af prostatacancer
DK4125842T3 (da) Samtidig indgivelse af mirdametinib og lifirafenib til anvendelse til behandling af kræftformer
DK3778592T3 (da) PSMA-målrettet radiolægemiddel til diagnosticering og behandling af prostatacancer
DK3773738T3 (da) Antistof-lægemiddelkonjugater og anvendelser deraf til behandling af cancer
IL269157A (en) Compositions and methods for treating cancer
DK4058474T3 (da) Sammensætninger og fremgangsmåder til behandling af egfr-positive kræftformer
DK3790879T3 (da) Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft
IL282232A (en) Diagnostic and therapeutic methods for sarcomatoid kidney cancer
DK4225297T3 (da) Kombinationsbehandling til behandling af cancer
LT3576740T (lt) Vėžio gydymas
DK3293201T3 (da) Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer